Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts

Chemical Research in Toxicology

Volumn 22, Issue 5, 2009, Pages 905-912

  Baskerville Abraham, Irene M ^a   Boysen, Gunnar ^a,b   Troutman, J Mitchell ^a   Mutlu, Esra ^a   Collins, Leonard ^a   DeKrafft, Kathryn E ^c   Lin, Wenbin ^c   King, Candice ^d   Chaney, Stephen G ^a,d   Swenberg, James A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GUANINE; PHOSPHORUS 32;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DOSE RESPONSE; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN;

ANIMALS; CARBOPLATIN; CATTLE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DNA; FEMALE; GUANINE; MICE; MICE, INBRED C57BL; RIBONUCLEOSIDES; TANDEM MASS SPECTROMETRY;

MUS;

EID: 67650002125     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx800481j     Document Type: Article

References (35)

1. Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J., and Sancar, A. (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. U.S.A. 91, 10394-10398.
2. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59, 3968-3971.
3. Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A., and Lippard, S. J. (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004-10013.
4. Dzagnidze, A., Katsarava, Z., Makhalova, J., Liedert, B., Yoon, M. S., Kaube, H., Limmroth, V., and Thomale, J. (2007) Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 27, 9451-9457.
5. Eastman, A. (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 34, 155-166.
6. Eastman, A. (1982) Separation and characterization of products resulting from the reaction of cis-diamminedichloroplatinum(II) with deoxyribonucleosides. Biochemistry 21, 6732-6736.
7. Eastman, A. (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine) platinum(II). Biochemistry 22, 3927-3933.
8. Fichtinger-Schepman, A. M., Vendrik, C. P., Dijk-Knijnenburg, W. C., de Jong, W. H., van der Minnen, A. C., Claessen, A. M., van der Velde-Visser, S. D., de Groot, G., Wubs, K. L., and Steerenberg, P. A. (1989) Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma. Cancer Res. 49, 2862-2867.
9. Terheggen, P. M., Floot, B. G., Lempers, E. L., van Tellingen, O., Begg, A. C., and den Engelse, L. (1991) Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother. Pharmacol. 28, 185-191.
10. Tilby, M. J., Johnson, C., Knox, R. J., Cordell, J., Roberts, J. J., and Dean, C. J. (1991) Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res. 51, 123-129.
11. Liedert, B., Pluim, D., Schellens, J., and Thomale, J. (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 34, e47.
12. 32P-postlabelling. Nucleic Acids Res. 23, 1300-1306.
13. 32P-postlabeling assay for the quantification of the major platinum-DNA adducts. Anal. Biochem. 275, 30-38.
14. Bassett, E., King, N. M., Bryant, M. F., Hector, S., Pendyala, L., Chaney, S. G., and Cordeiro-Stone, M. (2004) The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Res. 64, 6469-6475.
15. Gupta-Burt, S., Shamkhani, H., Reed, E., Tarone, R. E., Allegra, C. J., Pai, L. H., and Poirier, M. C. (1993) Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol. Biomarkers Prev. 2, 229-234.
16. Poirier, M. C., Reed, E., Shamkhani, H., Tarone, R. E., and Gupta-Burt, S. (1993) Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ. Health Perspect. 99, 149-154.
17. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirier, M. C. (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 84, 5024-5028.
18. Shamkhani, H., Anderson, L. M., Henderson, C. E., Moskal, T. J., Runowicz, C. D., Dove, L. F., Jones, A. B., Chaney, S. G., Rice, J. M., and Poirier, M. C. (1994) DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod. Toxicol. 8, 207-216.
19. Brouwers, E. E., Tibben, M. M., Pluim, D., Rosing, H., Boot, H., Cats, A., Schellens, J. H., and Beijnen, J. H. (2008) Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal. Bioanal. Chem. 391, 577-585.
20. Garcia, S. D., Montes-Bayon, M., Aguado, O. L., Blanco-Gonzalez, E., Sierra, L. M., and Sanz-Medel, A. (2008) In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal. Bioanal. Chem. 390, 37-44.
21. Iijima, H., Patrzyc, H. B., Dawidzik, J. B., Budzinski, E. E., Cheng, H. C., Freund, H. G., and Box, H. C. (2004) Measurement of DNA adducts in cells exposed to cisplatin. Anal. Biochem. 333, 65-71.
22. Le Pla, R. C., Ritchie, K. J., Henderson, C. J., Wolf, C. R., Harrington, C. F., and Farmer, P. B. (2007) Development of a liquid chromatography- electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples. Chem. Res. Toxicol. 20, 1177-1182.
23. Fasman, G. D. (1975) Handbook of Biochemistry and Molecular Biology, CRC Press, Cleveland, OH.
24. Cantor, C. R., Warshaw, M. M., and Shapiro, H. (1970) Oligonucleotide interactions. III. Circular dichroism studies of the conformation of deoxyoligonucleotides. Biopolymers 1059-1077.
25. Eastman, A. (1986) Reevaluation of interaction of cis-dichloro(ethylenediamine) platinum(II) with DNA. Biochemistry 25, 3912-3915.
26. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. (1987) Characterization of a cis-diamminedichloroplatinum(II)- resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47, 414-418.
27. Parker, R. J., Eastman, A., Bostick-Bruton, F., and Reed, E. (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87, 772-777.
28. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirier, M. C. (1988) The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 9, 1909-1911.
29. Banger, K. K., Lock, E. A., and Reed, C. J. (1996) Regulation of rat olfactory glutathione S-transferase expression. Investigation of sex differences, induction, and ontogenesis. Biochem. Pharmacol. 52, 801-808.
30. Roberts, R. B., Arteaga, C. L., and Threadgill, D. W. (2004) Modeling the cancer patient with genetically engineered mice: Prediction of toxicity from molecule-targeted therapies. Cancer Cell 5, 115-120.
31. Chesler, E. J., Miller, D. R., Branstetter, L. R., Galloway, L. D., Jackson, B. L., Philip, V. M., Voy, B. H., Culiat, C. T., Threadgill, D. W., Williams, R. W., Churchill, G. A., Johnson, D. K., and Manly, K. F. (2008) The Collaborative Cross at Oak Ridge National Laboratory: Developing a powerful resource for systems genetics. Mamm. Genome 19, 382-389.
32. Harrill, A. H., and Rusyn, I. (2008) Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity. Expert Opin. Drug Metab. Toxicol. 4, 1379-1389.
33. Lokich, J., and Anderson, N. (1998) Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann. Oncol. 9, 13-21.
34. Eastman, A. (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 34, 155-166.
35. Blommaert, F. A., Dijk-Knijnenburg, H. C., Dijt, F. J., den Engelse, L., Baan, R. A., Berends, F., and Fichtinger-Schepman, A. M. (1995) Formation of DNA adducts by the anticancer drug carboplatin: Different nucleotide sequence preferences in vitro and in cells. Biochemistry 34, 8474-8480.